Ultragenyx Pharmaceutical | RARE - Loan Capital

Stock Price
24.53
Daily Change
0.54 2.25%
Monthly
27.10%
Yearly
-35.57%
Q2 Forecast
23.58

Ultragenyx Pharmaceutical reported $763.74M in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Immunic USD 0 0 Jun/2024
Insmed USD 540.96M 1.24M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
Kyowa Hakko Kirin JPY 24.12B 5.27B Dec/2024
MacroGenics USD 70M 256K Dec/2025
Moderna USD 610M 584M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025
Xoma USD 94.38M 7.82M Sep/2025